KR20220104744A - 감염성 질환을 치료하기 위한 소분자 푸린 억제제 - Google Patents

감염성 질환을 치료하기 위한 소분자 푸린 억제제 Download PDF

Info

Publication number
KR20220104744A
KR20220104744A KR1020227019647A KR20227019647A KR20220104744A KR 20220104744 A KR20220104744 A KR 20220104744A KR 1020227019647 A KR1020227019647 A KR 1020227019647A KR 20227019647 A KR20227019647 A KR 20227019647A KR 20220104744 A KR20220104744 A KR 20220104744A
Authority
KR
South Korea
Prior art keywords
methyl
pyridin
oxy
dichlorophenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227019647A
Other languages
English (en)
Korean (ko)
Inventor
키이쓰 윌콕센
클라우딘 마파
Original Assignee
비피 애셋 브이, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비피 애셋 브이, 인크. filed Critical 비피 애셋 브이, 인크.
Publication of KR20220104744A publication Critical patent/KR20220104744A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020227019647A 2019-11-12 2020-11-12 감염성 질환을 치료하기 위한 소분자 푸린 억제제 Ceased KR20220104744A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934407P 2019-11-12 2019-11-12
US62/934,407 2019-11-12
PCT/US2020/060108 WO2021097009A1 (en) 2019-11-12 2020-11-12 Small molecule furin inhibitors for treating infectious diseases

Publications (1)

Publication Number Publication Date
KR20220104744A true KR20220104744A (ko) 2022-07-26

Family

ID=73793799

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019647A Ceased KR20220104744A (ko) 2019-11-12 2020-11-12 감염성 질환을 치료하기 위한 소분자 푸린 억제제

Country Status (8)

Country Link
US (1) US20230011571A1 (cg-RX-API-DMAC7.html)
EP (1) EP4058021A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023503852A (cg-RX-API-DMAC7.html)
KR (1) KR20220104744A (cg-RX-API-DMAC7.html)
CN (1) CN114929220A (cg-RX-API-DMAC7.html)
AU (1) AU2020382819A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157892A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021097009A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010914YA (en) 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
US20150051138A1 (en) * 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
US10150742B2 (en) * 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
SG11202010914YA (en) * 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors

Also Published As

Publication number Publication date
WO2021097009A1 (en) 2021-05-20
CN114929220A (zh) 2022-08-19
AU2020382819A1 (en) 2022-05-26
EP4058021A1 (en) 2022-09-21
JP2023503852A (ja) 2023-02-01
CA3157892A1 (en) 2021-05-20
US20230011571A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
ES2898069T3 (es) Derivados de N-(piridin-2-il)piridinosulfonamida y su uso en el tratamiento de la enfermedad
TW202322810A (zh) 作為kras抑制劑之喹啉化合物
CN105431420B (zh) 二杂芳基化合物及其用途
KR102823187B1 (ko) 푸린 억제제
AU2015339196A1 (en) Substituted tetrahydropyrans and method of use
AU2009274027A1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
EP2632260A1 (en) Leucine-rich repeat kinase enzyme activity
WO2024057013A1 (en) Nlrp3 modulators
IL273237B1 (en) New heterocyclic compounds as mglur7 modulators
CN105399756B (zh) Btk抑制剂及其用途
WO2020011147A1 (en) RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE
CN111704615A (zh) 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂
WO2022048498A1 (zh) Usp7抑制剂
KR20210005569A (ko) Rsv에 대한 활성을 갖는 헤테로방향족 화합물
US20260015360A1 (en) Biaryl derivatives and related uses
WO2021097009A1 (en) Small molecule furin inhibitors for treating infectious diseases
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN104530046B (zh) 二氮杂螺类化合物及其在药物中的应用
WO2021097002A1 (en) Use of pyridyloxypyrimidines for treating infectious diseases
WO2021097008A1 (en) Use of pyridyloxypyridines for treating infectious diseases
RU2799824C2 (ru) Ингибиторы фурина
WO2025155786A1 (en) Bicyclic tyrosine kinase 2 inhibitors and uses thereof
WO2025126115A1 (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
WO2025228367A1 (en) Pde3a/slfn12 disruptors, preparations, and uses thereof
TW202543612A (zh) 噻吩并吡啶化合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601